

XX. Myeloma & VIII. Cell Therapy Workshop

Organized by Blood Cancer Research Group & Czech Myeloma Group

OCTOBER 30 – 31, 2025

Quality Hotel Ostrava City | Czech Republic



SCIENTIFIC SESSIONS:

SESSION I – New Aspects of Modern Immunotherapies for Multiple Myeloma

SESSION II – NK Cell Advances: From Receptor Complexity to Engineered Therapies

SESSION III – Molecular Insights into Myeloma Progression and Dissemination

SESSION IV – Generation of Potent and Safe CAR T Cell Products

SESSION V – Academic Approach to CAR T Therapy

PANEL DISCUSSION – CHALLENGES AND ISSUES: Patenting and Licensing of Academic CAR T Cells

ORGANIZING COMMITTEE:

Prof. Roman Hájek, MD, PhD

Daniela Gachová, MSc

Hana Křížková, BSc

Jana Kotulová, PhD

QR code for live stream



THURSDAY, October 30**9:00 REGISTRATION****9:30 OPENING REMARKS**

Assoc. Prof. Michal Šimíček, PhD

SESSION I – New Aspects of Modern Immunotherapies for Multiple Myeloma

Chair: Assoc. Prof. Michal Šimíček, PhD

9:40 Novel Proximity-Labeling Approach to Investigate CAR-based Immune Synapse

Quynh Nhu Nguyen, MSc – Blood Cancer Research Group, Ostrava, CZ

9:55 Drug Delivery Systems with Polymer and Metal Nanoparticles in Multiple Myeloma

Gül Kozalak, PhD – Sabancı University, Istanbul, TR

10:10 Synthetic Lipid Rafts Formed by Cholesterol Nano-Patch Induce Early T Cell Activation

Yunmin Jung, PhD – Blood Cancer Research Group, Ostrava, CZ

10:30 COFFEE BREAK**SESSION II – NK Cell Advances: From Receptor Complexity to Engineered Therapies**

Chairs: Jana Kotulová, PhD, Zuzana Chyra, PhD

10:50 Fitness of Immunotherapeutic NK Cells for Acute Myeloid Leukemia: Challenges and Opportunities

Jan Frič, PhD – Institute of Hematology and Blood Transfusion, Prague, CZ

11:05 Killer Cell Immunoglobulin-Like Receptor (KIR) Isoforms – the Next Level of Heterogeneity

Robin Klieber, MSc – Laboratory of Tumour Biology and Immunotherapy, Pilsen, CZ

11:20 Disruption of NKG2A:HLA-E Interactions to Improve NK Cell Activation Against Haematological Malignancies

Assoc. Prof. Matthew Blunt, PhD (online) – University of Southampton, Southampton, UK

11:40 LUNCH BREAK

SESSION III – Molecular Insights into Myeloma Progression and Dissemination

Chairs: Assoc. Prof. Tomáš Jelínek, MD, PhD, Tereza Ševčíková, PhD

13:15 Breaking the Silence: Unveiling Genomic Instability in Hidden Regions of the Myeloma Genome

Aneta Mikulášová, PhD – Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

13:30 Aberrant Single-Cell Phenotype and Clinical Implications of Genotypically Defined Polyclonal Plasma Cells in Myeloma

Francesca Lazzaroni, PhD – University of Milan, IT

13:45 Circulating Tumor Cells in Myeloma Are a Compound Biomarker High-Risk Genomic Alterations and Tumor Burden

Luca Bertamini, MD – Erasmus MC Cancer Institute, Rotterdam, NL

14:00 The Impact of Bone Marrow Immune Cells on Therapy Response in Newly-Diagnosed Myeloma Patients

Assoc. Prof. Tom Cupedo, PhD – Erasmus MC Cancer Institute, Rotterdam, NL

14:15 Why Myeloma Cells Circulate: Bone Marrow Biology and Molecular Profiles of High CTC Burden

Daniel Bílek, MSc – Blood Cancer Research Group, Ostrava, CZ

14:30 Genomic and Immune Determinants of Response to Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy in Newly Diagnosed Multiple Myeloma

Michael Durante, MD, PhD – Sylvester Comprehensive Cancer Center, Miami, USA

14:50 COFFEE BREAK**POSTER SESSION**

Committee: Assoc. Prof. Sabina Ševčíková, PhD
Yunmin Jung, PhD
Juli Rodríguez Bagó, PhD (chair)

15:00 All posters**15:30 Spotlight Presentations of Preselected Posters****16:00 CLOSING REMARKS**

Prof. Roman Hájek, MD, PhD

18:00 DINNER

FRIDAY, October 31**SESSION IV – Generation of Potent and Safe CAR T Cell Products**

Chair: Piotr Celichowski, PhD

9:30 Epigenome Editing to Shape CAR T Cells with Potentially Beneficial Features

Claudio Mussolino, PhD – Research Group Genome and Epigenome Engineering, Freiburg, DE

9:45 Jumping Genes for Therapeutic Cell Engineering

Prof. Zoltan Ivics, PhD – Institute of Clinical Immunology, Leipzig, DE

10:10 CD4 T Cell Exhaustion and the Epigenetic Regulation of these Processes

Prof. Elzbieta Sarnowska, PhD – National Research Institute of Oncology, Warsaw, PL

10:25 Base Editing Strategy Enables the Generation of NK-resistance Allogenic CAR T Cells

Jamal Alzubi, PhD – Blood Cancer Research Group, Ostrava, CZ

10:45 COFFEE BREAK**11:00 EVALUATION AND ANNOUNCEMENT OF BEST POSTERS****SESSION V – Academic Approach to CAR T Therapy**

Chair: Prof. Roman Hájek, MD, PhD

11:15 CAR-T Therapy Availability in CEE Region of EU: 2025

Prof. Roman Hájek, MD, PhD – Blood Cancer Research Group, Ostrava, CZ

11:30 Non-Viral Production of CAR-T Cells: Advancing Clinical Manufacturing Using PiggyBac and Linear DNA/ mRNA-Based Transposase Systems

Assoc. Prof. Irena Koutná, PhD – St. Anne's University Hospital, Brno, CZ

11:45 Phase I Trials of CAR-T Cells against CD19 Positive and CD123 Positive Haematological Malignancies

Jan Vydra, MD, PhD – Institute of Hematology and Blood Transfusion, Prague, CZ

12:00 ROUNDTABLE DISCUSSION – CHALLENGES AND ISSUES: Patenting and Licensing of Academic CAR-T Cells

Petr Lesný, MD, PhD – Institute of Hematology and Blood Transfusion, Prague, CZ

12:40 CLOSING REMARKS OF THE MCTW 2025

Prof. Roman Hájek, MD, PhD

12:45 LUNCH BREAK